PATENT CLAIM ANALYSIS

Application Number: 15941644
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["424", "408000"]

Abstract:
Disclosed herein are sustained release Liothyronine oral capsule formulations, methods of making the formulations and use to treat hypothyroidism, a thyroid deficient disease state, or thyroid dysfunction.

Claim (Index 2):
The capsule formulation of  claim 1 , comprising liothyronine sodium equivalent to about 1, about 2, about 3, about 5, about 7.5, about 10, about 12.5, about 15, about 17.5, about 20 or about 25 micrograms of liothyronine.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.14815
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15912438', '13498751', '12097163', '14776386', '14062759']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7186507922993652
- 35 USC 102 Novelty (BERT): 0.4929009724303057
- Combined Prediction Score: 0.6960758103124594
- Mean Citation Score: 224.737068
- Max Citation Score: 237.49814
- Similarity Product: 177.67992789028884

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test